Nanocapsules show multiple benefits in Parkinson’s model

Scientists have developed nanocapsules designed to treat Parkinson’s disease by simultaneously increasing dopamine levels and reducing neuroinflammation. In a recent study, these nanocapsules improved both motor and cognitive function in mice with Parkinson’s. The researchers believe this dual-target approach could better control disease progression compared to current treatments. The nanocapsules are engineered to cross the blood-brain barrier (BBB), a major hurdle in neurological treatment, using a combination of specialized coatings. These capsules are made with dopamine and catalase—an enzyme that helps reduce inflammation. They showed stability and effectiveness in a lab model, reducing oxidative stress and improving mitochondrial function. In mice, they crossed the BBB, raised dopamine levels, reduced neuroinflammation, and restored normal dopamine signaling without affecting other organs. By tackling dopamine deficiency and neuroinflammation together, the scientists propose a synergistic treatment that not only alleviates symptoms but may also slow disease progression. They highlighted this innovation as a promising direction for neurodegenerative disease therapy.